Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7650517> ?p ?o }
Showing triples 1 to 92 of
92
with 100 triples per page.
- Q7650517 subject Q7579524.
- Q7650517 subject Q8297734.
- Q7650517 subject Q8376083.
- Q7650517 subject Q8529670.
- Q7650517 subject Q8703495.
- Q7650517 subject Q8727262.
- Q7650517 subject Q8872471.
- Q7650517 subject Q8919936.
- Q7650517 abstract "Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia. It is effective for insomnia, at least for four weeks and as compared to a placebo.Suvorexant is a selective, dual orexin receptor antagonist made by Merck & Co. It was approved for sale by the U.S. Food and Drug Administration (FDA) on August 13, 2014. The U.S. Drug Enforcement Administration (DEA) has placed it on the list of schedule IV controlled substances. The drug became available in Japan in November 2014 and in the United States in February 2015.".
- Q7650517 atcPrefix "None".
- Q7650517 bioavailability "82.0".
- Q7650517 casNumber "1030377-33-3".
- Q7650517 fdaUniiCode "081L192FO9".
- Q7650517 iupacName "[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone".
- Q7650517 pubchem "24965990".
- Q7650517 thumbnail Suvorexant.svg?width=300.
- Q7650517 wikiPageExternalLink www.belsomra.com.
- Q7650517 wikiPageExternalLink the-big-sleep-2.
- Q7650517 wikiPageWikiLink Q1070023.
- Q7650517 wikiPageWikiLink Q1077823.
- Q7650517 wikiPageWikiLink Q118551.
- Q7650517 wikiPageWikiLink Q11995.
- Q7650517 wikiPageWikiLink Q12029.
- Q7650517 wikiPageWikiLink Q1321905.
- Q7650517 wikiPageWikiLink Q14916187.
- Q7650517 wikiPageWikiLink Q167149.
- Q7650517 wikiPageWikiLink Q17.
- Q7650517 wikiPageWikiLink Q174876.
- Q7650517 wikiPageWikiLink Q18026851.
- Q7650517 wikiPageWikiLink Q18026854.
- Q7650517 wikiPageWikiLink Q18355303.
- Q7650517 wikiPageWikiLink Q1869874.
- Q7650517 wikiPageWikiLink Q189561.
- Q7650517 wikiPageWikiLink Q204711.
- Q7650517 wikiPageWikiLink Q20707990.
- Q7650517 wikiPageWikiLink Q213511.
- Q7650517 wikiPageWikiLink Q218842.
- Q7650517 wikiPageWikiLink Q246710.
- Q7650517 wikiPageWikiLink Q247489.
- Q7650517 wikiPageWikiLink Q269829.
- Q7650517 wikiPageWikiLink Q30.
- Q7650517 wikiPageWikiLink Q30612.
- Q7650517 wikiPageWikiLink Q3184856.
- Q7650517 wikiPageWikiLink Q407883.
- Q7650517 wikiPageWikiLink Q408637.
- Q7650517 wikiPageWikiLink Q410291.
- Q7650517 wikiPageWikiLink Q410857.
- Q7650517 wikiPageWikiLink Q410943.
- Q7650517 wikiPageWikiLink Q411229.
- Q7650517 wikiPageWikiLink Q419968.
- Q7650517 wikiPageWikiLink Q422229.
- Q7650517 wikiPageWikiLink Q422585.
- Q7650517 wikiPageWikiLink Q422618.
- Q7650517 wikiPageWikiLink Q425490.
- Q7650517 wikiPageWikiLink Q4355941.
- Q7650517 wikiPageWikiLink Q461809.
- Q7650517 wikiPageWikiLink Q47270.
- Q7650517 wikiPageWikiLink Q47273.
- Q7650517 wikiPageWikiLink Q5014970.
- Q7650517 wikiPageWikiLink Q5161126.
- Q7650517 wikiPageWikiLink Q5165931.
- Q7650517 wikiPageWikiLink Q622899.
- Q7650517 wikiPageWikiLink Q7101692.
- Q7650517 wikiPageWikiLink Q7388914.
- Q7650517 wikiPageWikiLink Q7539762.
- Q7650517 wikiPageWikiLink Q7579524.
- Q7650517 wikiPageWikiLink Q8297734.
- Q7650517 wikiPageWikiLink Q8376083.
- Q7650517 wikiPageWikiLink Q8529670.
- Q7650517 wikiPageWikiLink Q8703495.
- Q7650517 wikiPageWikiLink Q8727262.
- Q7650517 wikiPageWikiLink Q8872471.
- Q7650517 wikiPageWikiLink Q8919936.
- Q7650517 wikiPageWikiLink Q899107.
- Q7650517 wikiPageWikiLink Q928770.
- Q7650517 wikiPageWikiLink Q929737.
- Q7650517 wikiPageWikiLink Q9635.
- Q7650517 atcPrefix "None".
- Q7650517 bioavailability "82.0".
- Q7650517 casNumber "1030377".
- Q7650517 iupacName "[-4--7-methyl-1,4-diazepan-1-yl][5-methyl-2-phenyl]methanone".
- Q7650517 pubchem "24965990".
- Q7650517 unii "81".
- Q7650517 type ChemicalSubstance.
- Q7650517 type Drug.
- Q7650517 type ChemicalObject.
- Q7650517 type Thing.
- Q7650517 type Q8386.
- Q7650517 comment "Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia. It is effective for insomnia, at least for four weeks and as compared to a placebo.Suvorexant is a selective, dual orexin receptor antagonist made by Merck & Co. It was approved for sale by the U.S. Food and Drug Administration (FDA) on August 13, 2014. The U.S. Drug Enforcement Administration (DEA) has placed it on the list of schedule IV controlled substances.".
- Q7650517 label "Suvorexant".
- Q7650517 depiction Suvorexant.svg.
- Q7650517 homepage www.belsomra.com.